ASCO 2020 Annual Meeting - Virtual Scientific Program
ASCO 2020 Prostate Cancer
- ASCO 2020: Genitourinary Cancers Highlights – Prostate, Testicular, and Penile Cancers
- ASCO 2020: A Phase II Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
- ASCO 2020: Short-Term Adjuvant Versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Phase III Trials
- ASCO 2020: Evaluation of a Mainstream Model of Genetic Testing for Men with Prostate Cancer
- ASCO 2020: CYCLONE 2: A Phase II, Randomized, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or Without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO 2020 Bladder Cancer
- ASCO 2020: Genitourinary Cancers Highlights – Kidney and Bladder
- ASCO 2020: Checkpoint Inhibition in Metastatic Urothelial Carcinoma: Timing is Everything
- ASCO 2020: JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Care vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma
- ASCO 2020: DUTRENEO Trial: A Randomized Phase II Trial of DUrvalumab and TREmelimumab Versus Chemotherapy as a NEOadjuvant Approach to Muscle-Invasive Urothelial Bladder Cancer Patients Prospectively Selected by an Interferon-Gamma Immune Signature
- ASCO 2020: Discussant: Novel Immunotherapy-Based Therapy in Metastatic Urothelial Cancers and Rare Genitourinary Malignancies
ASCO 2020 Kidney Cancer
- ASCO 2020: PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704)
- ASCO 2020: Discussant: Rare Variant Histologies in Renal Cell Carcinoma: Making the Unclear Be More Clear
- ASCO 2020: Association of Gene Expression with Clinical Outcomes in Patients with Renal Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-427
- ASCO 2020: Evaluation of Predictive Biomarkers for Nivolumab in Patients with Metastatic Clear Cell Renal Cell Carcinoma from the CheckMate-025 Trial
- ASCO 2020: Phase II trial of Lenvatinib plus Pembrolizumab for Disease Progression after PD-1/PD-L1 Immune Checkpoint Inhibitor in Metastatic Clear Cell Renal Cell Carcinoma
ASCO 2020 Testicular and Penile Cancer
- ASCO 2020: A 13-Years Follow-up Analysis of a Phase III Trial Cohort: Late Toxicities and Recurrences in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumor After One Cycle of Adjuvant BEP Versus Primary Retroperitoneal Lymph Node Dissection
- ASCO 2020: Late Toxicities and Recurrences in Patients with Clinical Stage 1 Nonseminomatous Germ Cell Tumor After 1 Cycle of Adjuvant BEP vs. Primary Retroperitoneal Lymph Node Dissection – a 13 Years Follow-up Analysis of a Phase 3 Trial Cohort
- ASCO 2020: Phase II Study of Nivolumab and Ipilimumab for Advanced Rare Genitourinary Cancers
ASCO 2020 Press Releases
- Epic Sciences to Present Multiple Abstracts at ASCO 2020 Highlighting the Importance of CTCs in Liquid Biopsy Data Characterizes the Role of CTCs in Cancer Prognosis and Patient Care
- Phase III Trial Shows Avelumab an Immunotherapy Treatment for Advanced Urothelial Cancer Prolongs Overall Survival
- Early Data Show Cancer Progression Associated With Increased Risk of Death in Patients With COVID-19
- Darolutamide Plus Androgen Deprivation Therapy Showed Significant Improvement in Overall Survival with Proven Efficacy and Tolerability in Men with Non-Metastatic Castration-Resistant Prostate Cancer
- Foundation Medicine and Collaborators to Share New Data During the ASCO20 Virtual Scientific Program Showcasing the Importance of Comprehensive Genomic Profiling (CGP) in Informing Advanced Cancer Clinical Decision-Making